Goldman Sachs tips CSL share price to climb to $223.00

The CSL Limited (ASX:CSL) share price could keep climbing higher according to Goldman Sachs…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Ahead of its Global Healthcare Conference in the United States, this morning Goldman Sachs took a deep dive into its forecasts and target prices across its Australian healthcare coverage.

One company that came out of its review favourably was CSL Limited (ASX: CSL). According to the note, CSL remains the broker's top pick in the local healthcare sector and has increased its target price to $223.00.

This implies potential upside of around 9.4% from its last close price.

Why does Goldman Sachs rate CSL as a buy?

One reason Goldman is bullish on CSL is that it believes the strength the biotechnology giant is experiencing in Immunoglobulins outweighs operational risks.

The broker notes that the Immunoglobulins business is accelerating as its legacy products wind down. Further, recent industry feedback is consistently positive on the near/mid-term trajectory of Immunoglobulins.

In light of this, Goldman has "forecast double digit 3-year CAGRs for both Privigen (+10%) and Hizentra (+13%), driven by improved awareness/diagnosis and a positive shift onto the neurological indication, CIDP."

In addition, the broker notes that the current pricing environment is supportive and expects it to contribute to a stable gross margin development across the Behring business "despite the real threat from accelerating donor fee inflation and last litre."

Another reason to be positive is the company's Speciality products. Goldman has been positively surprised at the performance of this side of the business.

"Although Takhzyro (lanadelumab) is now widely available, Haegarda continues to take new patient starts in all markets in which it has launched. We continue to assume a distinct minority of new starts but relative stickiness in existing share."

Overall, the broker believes CSL is well-placed to grow its earnings per share at a strong rate through to at least FY 2021.

What about its peers?

The broker also reiterated its buy rating on Cochlear Limited (ASX: COH) and increased the price target on the hearing solutions company's shares to $209.00.

However, Goldman remains bearish on Ramsay Health Care Limited (ASX: RHC) and has once again rated its shares as a sell, albeit with an improved price target of $57.00. The broker has concerns over the decline in private health insurance participation rates and cost inflation, particularly with nurse wages.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia has recommended Cochlear Ltd. and Ramsay Health Care Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Man smiling at a laptop because of a rising share price.
Opinions

My 2 favourite ASX sectors to invest in

Finding your groove can help your investing success.

Read more »

Legendary share market investing expert and owner of Berkshire Hathaway Warren Buffett
Opinions

3 things I learned from Warren Buffett being the CEO of Berkshire Hathaway

The Oracle from Omaha is in his last year as CEO.

Read more »

A male ASX 200 broker wearing a blue shirt and black tie holds one hand to his chin with the other arm crossed across his body as he watches stock prices on a digital screen while deep in thought
Share Market News

5 things to watch on the ASX 200 on Tuesday

Here's what to expect on the local market today.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a rough trading day for ASX stocks this Monday.

Read more »

A bland looking man in a brown suit opens his jacket to reveal a red and gold superhero dollar symbol on his chest.
Broker Notes

Bell Potter names more of the best ASX 200 stocks to buy in May

These stocks could be best buys this month according to the broker.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Oil worker using a smartphone in front of an oil rig.
Energy Shares

ASX 200 energy shares plunge on shock OPEC move

ASX 200 energy shares like Woodside and Santos are tumbling on Monday. Let’s find out why.

Read more »

Two happy excited friends in euphoria mood after winning in a bet with a smartphone in hand.
Share Gainers

Why 4DMedical, Gold Road, Syrah, and Tyro shares are racing higher today

These shares are starting the week strongly. But why?

Read more »